Product Name :
GDC-0339
Description:
GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma.
CAS:
1428569-85-0
Molecular Weight:
465.50
Formula:
C20H22F3N7OS
Chemical Name:
5-amino-N-5-[(4R,5R)-4-amino-5-fluoroazepan-1-yl]-1-methyl-1H-pyrazol-4-yl-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide
Smiles :
CN1N=CC(NC(=O)C2N=C(SC=2N)C2C(F)=CC=CC=2F)=C1N1CC[C@@H](N)[C@H](F)CC1
InChiKey:
NHXVGMQFCYBLTL-ZWNOBZJWSA-N
InChi :
InChI=1S/C20H22F3N7OS/c1-29-20(30-7-5-10(21)13(24)6-8-30)14(9-26-29)27-18(31)16-17(25)32-19(28-16)15-11(22)3-2-4-12(15)23/h2-4,9-10,13H,5-8,24-25H2,1H3,(H,27,31)/t10-,13-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Bexotegrast supplier
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma.|Product information|CAS Number: 1428569-85-0|Molecular Weight: 465.50|Formula: C20H22F3N7OS|Chemical Name: 5-amino-N-5-[(4R,5R)-4-amino-5-fluoroazepan-1-yl]-1-methyl-1H-pyrazol-4-yl-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide|Smiles: CN1N=CC(NC(=O)C2N=C(SC=2N)C2C(F)=CC=CC=2F)=C1N1CC[C@@H](N)[C@H](F)CC1|InChiKey: NHXVGMQFCYBLTL-ZWNOBZJWSA-N|InChi: InChI=1S/C20H22F3N7OS/c1-29-20(30-7-5-10(21)13(24)6-8-30)14(9-26-29)27-18(31)16-17(25)32-19(28-16)15-11(22)3-2-4-12(15)23/h2-4,9-10,13H,5-8,24-25H2,1H3,(H,27,31)/t10-,13-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 52 mg/mL (111.71 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Efalizumab Cytoskeleton |Shelf Life: ≥12 months if stored properly.PMID:31755309 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|GDC-0339 is cytostatic, with an IC50 of 0.1 μM for MM.1S cells. GDC-0339 treatment reveals a constellation of Pim downstream signaling events consistent with inhibition of Pim kinases.|In Vivo:|GDC-0339 (1-300 mg/kg; p.o; daily; for 21 days) is efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models. GDC-0339 has a half-life of t1/2=0.9 h.|Products are for research use only. Not for human use.|
